PATRICK J. LEAHY, VERMONT, CHAIRMAN

HERB KOHL, WISCONSIN
DIANNE FEINSTEIN, CALIFORNIA
CHARLES E. SCHUMER, NEW YORK
RICHARD J. DURBIN, ILLINOIS
SHELDON WHITEHOUSE, RHODE ISLAND
AMY KLOBUCHAR, MINNESOTA
AL FRANKEN, MINNESOTA
CHRISTOPHER A. COONS, DELAWARE
RICHARD BLUMENTHAL, CONNECTICUT

CHARLES E. GRASSLEY, IOWA
ORRIN G. HATCH, UTAH
JON KYL, ARIZONA
JEFF SESSIONS, ALABAMA
LINDSEY O. GRAHAM, SOUTH CAROLINA
JOHN CORNYN, TEXAS
MICHAEL S. LEE, UTAH
TOM COBURN, OKLAHOMA

BRUCE A. COHEN, *Chief Counsel and Staff Director*
KOLAN L. DAVIS, *Republican Chief Counsel and Staff Director*

United States Senate
COMMITTEE ON THE JUDICIARY
WASHINGTON, DC 20510–6275

May 4, 2011

Via Electronic Transmission

Nancy A. Brown
Chief Executive Officer
American Heart Association
7272 Greenville Avenue
Dallas, TX 75231

Dear Ms. Brown:

In December 2009, I asked for an accounting of industry funding that the American Heart Association (AHA) receives from pharmaceutical and medical device companies as well as foundations established by these companies or the insurance industry. I appreciate your response, which I have attached to this letter. I write today to follow up on any efforts by your organization to improve transparency and accountability in its relationships with the pharmaceutical and device industries.

As I stated in my previous letter, I started my inquiry, in part, as a result of accounts documenting the lack of transparency in financial relationships between the pharmaceutical industry and nonprofit health and medical organizations. Specifically, I cited the April 2008 article in *The Wall Street Journal*, which reported that industry representatives, including ten major drug companies, had formed a coalition to promote looser restrictions on off-label marketing.[1] The coalition had asked the National Alliance on Mental Illness (NAMI) to speak in favor of this issue.

In response to my concerns in my April 2009 letter to NAMI, NAMI began to voluntarily disclose to the public any amount of funding exceeding $5,000 that it received from pharmaceutical companies and foundations on its website. Further, NAMI began to provide a brief description of the purpose of the funding on its website. I commend NAMI for its leadership and had hoped that when I reached out to your organization and 32 others, your organization would follow NAMI's example and begin posting similar funding information on AHA's website.

As of the date of this letter, it appears that no additional information regarding your organization's industry funding has been posted on the AHA's website. If AHA is currently

[1] Alicia Mundy, "Off-Label Use of Drugs Gets a Push --- Big Pharma Lobbies Washington to Relax Rules on Marketing," *The Wall Street Journal*, April 18, 2008.

taking steps to enhance the transparency of its financial relationships with the pharmaceutical and device industries, I would appreciate information regarding those steps. If not, please explain why your organization does not support the disclosure of funding it receives from pharmaceutical and device companies.

The Medicare Payment Advisory Commission (MedPAC) recommended in a report to Congress in March 2009 that Congress require that pharmaceutical and device companies report their financial relationships with physician groups, patient organizations, and others. More specifically MedPAC said the following:

> Given the potential benefits of public reporting, we recommend that the Congress mandate the reporting of comprehensive information on industry relationships with physicians and other health care entities and that the Secretary post this information on a public searchable website.[2]

MedPAC then went on to say in Recommendation 5-1 that**:**

> The Congress should require all manufacturers and distributors of drugs, biologicals, medical devices, and medical supplies (and their subsidiaries) to report to the Secretary their financial relationship with:…physician groups and other prescribers…patient organizations; and professional organizations.[3]

I look forward to working with you and other health and medical organizations to further increase sunshine on financial relationships.

Thank you for your cooperation and attention in this matter. I would appreciate a response by May 25, 2011. If you have any questions, please do not hesitate to contact Brian Downey for the Committee on the Judiciary at (202) 224-5225.

Sincerely,

Charles E. Grassley
Ranking Member

Attachments

---

[2] Medicare Payment Advisory Commission, "Public reporting of physicians' financial relationships," Report to Congress: Medicare Payment Policy, March 2009.
[3] *Id.*

Attachment

Chairman of the Board
Neil M. Meltzer, MPH

President
Clyde W. Yancy, MD, FAHA

Chairman-elect
Debra W. Lockwood, CPA

President-elect
Ralph L. Sacco, MD, FAHA

Immediate Past Chairman of the Board
David A. Josserand

Immediate Past President
Timothy J. Gardner, MD, FAHA

Secretary-Treasurer
William H. Roach Jr., Esq.

Directors
Donna K. Arnett, PhD, FAHA
Kenneth D. Bloch, MD, FAHA
Mary A. Caldwell, RN, PhD, FAHA
Stephen R. Daniels, MD, PhD, FAHA
Pierre B. Fayad, MD, FAHA
Debra A. Geihsler
Larry B. Goldstein, MD, FAHA
Max Gomez, PhD
Ron W. Haddock
Pamela K. Knous
Paula Lank, BSN
Mark B. McClellan, MD, PhD
Hon. Judith F. Olson
David A. Spina
Gordon F. Tomaselli, MD, FAHA

Chief Executive Officer
Nancy A. Brown

Chief Mission Officer
Meighan Girgus

Chief Administrative Officer & Chief Financial Officer
Sunder D. Joshi

Chief Operating Officer Field Operations & Development
Gordon L. McCullough

Chief Science Officer
Rose Marie Robertson, MD, FAHA

Executive Vice President Communications
Matthew Bannister

Executive Vice President ECC Programs
Michael C. Bell

Executive Vice President Field Health Strategies
Robyn Lee Landry, APR

Executive Vice President Corporate Secretary & General Counsel
David Wm. Livingston, Esq.

Executive Vice President Consumer Health
Kathy Rogers

Executive Vice President Advocacy
Mark A. Schoeberl

Executive Vice President Development
Suzie Upton

Executive Vice President Technology & Customer Strategies
Michael Wilson

American Heart Association. | American Stroke Association.
Learn and Live.

National Center
7272 Greenville Avenue • Dallas, Texas 75231-4596
Tel 214.373.6300 • americanheart.org

January 27, 2010

Via Hand Delivery

Hon. Charles E. Grassley
c/o Brian Downey
Committee on Finance
United States Senate
219 Dirksen Senate Office Building
Washington, DC 20510-6200

Dear Senator Grassley:

This letter is in response to your letter of December 7, 2009, to the American Heart Association ("AHA") requesting information relating to funding from pharmaceutical, device, insurance and their related foundations and AHA policies related to transparency. AHA intends to fully cooperate with your inquiry. We value the trust placed in us by our donors, supporters and the general public, and we feel the best way to continue to earn that trust is to make the Association's finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the Better Business Bureau's Wise Giving Alliance (WGA), the premier organization evaluating charitable organizations.

By way of background, most of the revenue recorded by the American Heart Association comes from individual donors who pay their donations to the AHA during the year and from single and multi-year commitments from individuals and corporations. The bulk of the revenue comes from individual contributions, accounting for 46.0 percent, while contributions from businesses and corporations account for 27.9 percent.

Financial support from corporations allows the American Heart Association's programs and campaigns to more effectively advance our mission of building healthier lives, free of heart disease and stroke. Founded in 1924, the American Heart Association today is the nation's oldest and largest voluntary health organization dedicated to fighting heart disease and stroke. These diseases, America's #1 and # 3 killers, along with other cardiovascular diseases claim nearly 870,000 lives a year. In fiscal year 2008/09, the AHA invested more than $525 million in research, professional and public education,

advocacy and community service programs to help all Americans live longer, healthier lives.

Since November 2006, AHA has disclosed contributions from pharmaceutical and device companies on its web site. At that time, AHA's CEO Cass Wheeler wrote to the Board of Directors the following:

> As you know, one of my goals is for the AHA always to be as transparent as possible in our communication to the public. We strive to do everything we can to earn – and keep – the public's trust. In an effort to demonstrate complete transparency, we have decided to post on our website the contributions that we receive at National Center from pharmaceutical and device companies, and to show the percentage this represents of overall revenue. We have included all of these mission-related gifts from pharmaceutical companies and device manufacturers that contributed more than $100,000 to the National Center. To my knowledge, we are one of the first voluntary health organizations to take this important step.

Pharmaceutical and device company contributions represent a small fraction of AHA's total revenue. For the most recent audited fiscal year 2008/09, National Center contributions were just 3.6% of total revenue. Even though your request asks for expanded information beyond pharmaceutical and device company contributions, in the 2008/09 fiscal year, National Center and the largest Affiliate contributions from pharmaceutical, device, insurance, and their foundations still represent only 4.0% of AHA's total revenue. AHA relies on a diverse donor base and strong policies to achieve its goals for improving health. AHA has among the strongest corporate relations and conflict of interest policies of any voluntary health organization. We believe these policies, which are summarized in this letter and provided in the attachments[1], will demonstrate to you the American Heart Association's commitment to transparency while working with industry to improve medical knowledge and care for the American public. Below are the responses to your requests.

Accounting of industry funding (i.e., grants, donations, sponsorships or other transfer of value to AHA from pharmaceutical companies, medical device companies, their foundations, and insurance companies) from January 2006 to the present in chart form showing: year, name of company, amount, and reason for funding.

Chart 1 is a summary of contributed[2] revenue and cash received from pharmaceutical, device, and insurance companies and their foundations from

---

[1] The documents produced with this correspondence have been designated Chart 1 and 2 and Tabs 1-10; they also carry the Bates designations AHA-000001 through AHA-001083.

[2] Please note that based on your request, and consistent with our discussion with your staff on January 25, 2010, AHA is providing contributed revenue figures and not earned revenue figures. This is also consistent with AHA's public disclosures and National Health Council standards (see discussion below). Contributions include amounts received or pledged for which the donor receives no direct tangible benefit in return (in this respect contributions differ from exchange transactions). For AHA's internal reporting purposes, contributions are categorized as donations from individuals (outright gifts), foundations and corporations (including corporate relations national sponsorships), endowment donations, memorials/tributes, and direct response. In

July 1, 2005 through June 30, 2009. AHA is on a July 1 – June 30 fiscal year, and this represents four complete and audited AHA fiscal years. Chart 1 also includes the corresponding pharmaceutical and device contributions that AHA has posted on its web site.

Beginning with fiscal year 2006/2007, AHA has posted the contributions as cash received rather than revenue booked. When revenue is booked, the entire amount of a multi-year commitment is booked as revenue in the year the contract was signed, even though the cash is received over several years. As a result the postings reflect significant revenue fluctuations from year to year and reflect future expected payments rather than funds actually received. AHA believes that cash received each year better reflects the level of support provided by these sponsors for AHA programs.

Chart 2 is a list of the individual company contributions received from pharmaceutical, device, and insurance companies and their foundations from July 1, 2005 through June 30, 2009. The figures provided in Chart 1 and 2 include National Center revenue plus some Affiliate revenue. Affiliates generally report revenue as corporate revenue as distinct from individual donations, and do not identify specific industry categories for corporate contributions. Corporate contributions to Affiliates help raise money for local events, such as galas, Heart Walks, and Go Red For Women luncheons. For the last two complete fiscal years, we are able to determine from existing records the top 10 corporate contributors for each Affiliate. Those that were from pharmaceutical, device, or insurance companies or their foundations have been reported on Chart 1 and 2. However, this information is not readily available for prior fiscal years, since there was no requirement in place to track this information. The majority of corporate funding occurs at the National Center level because the National Center is responsible for regional and Association-wide corporate relationships. Corporate funding helps with the design, development and implementation of AHA programs and the website. It is the National Center rather than the Affiliates that is responsible for developing AHA scientific standards and guidelines, publishing AHA scientific journals, conducting AHA scientific conferences and meetings, national programs, and administering the AHA web site.

Since 2006, AHA disclosed pharmaceutical and device corporate contributions on its web site; see National Center Support from Pharmaceutical Companies and Device Manufacturers. The 2008-2009 information provides the amount of total "corporate" contributions in compliance with the recently revised National Health Council Standard 9 as discussed below. Since no corporation contributed an amount that required identification on Schedule B of AHA's IRS Form 990, AHA's current disclosure does not include contributions from every corporate supporter. However, AHA will continue to disclose on its web site the name of the company and the contribution amount from pharmaceutical and device companies contributing at the national level. For purposes of NHC Standard 9, financial support includes money transferred for events and program activities, irrespective of whether the corporation treats such support

---

contrast, earned revenue includes amounts earned through exchange transactions, gains and losses, investment income and other miscellaneous non-campaign or non-public support income.

as a charitable donation or business expense for purposes of its filings with the Internal Revenue Service. However, fee-for-service transactions, such as advertising fees, subscription and publications sales, exhibitor fees and meeting registrations need not be disclosed.

1. Explain policies for accepting industry funding and the disclosure requirements for top executives and board members, specifically:

a. Explain what policies, if any, AHA plans to adopt to assure transparency of funding in order to provide a greater public trust in the independence of the AHA.

The AHA currently has multiple policies and procedures in place to help assure transparency of funding and public trust in the AHA.

Corporate Relations Policy

AHA's Corporate Relations Policy applies to the use of AHA's name, servicemarks, or other intellectual property by a for-profit corporation in commercial channels or mass media, and/or in connection with a commercial product, service or company. Typical corporate relationships include sponsorships that underwrite AHA programs and events, promotions in which the company includes an appeal for support of an AHA program or event in the marketing of its products or services, manufacture and/or marketing of AHA-branded or licensed products, and certification of food products meeting AHA nutrition criteria.

All corporate relationships are governed by AHA's Corporate Relations Policy which is enclosed at **Tab 1**. This policy provides when and how AHA's name and servicemarks may be used, requires a "proclaimer" or "statement of relationship" describing the relationship with the corporation, requires AHA approval of materials related to the relationship, requires a written contract, and requires advance approval of the corporation's advertising and promotional materials that display the AHA name or marks.

AHA's Corporation Relations Policy complies with the National Health Council's Standards of Excellence™ Certification Program. NHC is made up of more than 100 national health-related organizations, of which AHA is a voluntary health agency member. Membership requires compliance with the NHC Standards. In June 2009, AHA updated its Corporate Relations Policy to align with NHC's updated Standard 9 requiring disclosure of corporate support. Pertinent excerpts from Standard 9:

> With regard to section c): The organization must, unless otherwise prohibited by law, disclose financial support it receives as a result of corporate relationships. For purposes of this standard, financial support includes money transferred for events and program activities, irrespective of whether the corporation treats such support as a charitable donation or business expense for purposes of its filings with

> the Internal Revenue Service. However, fee-for-service transactions, such as advertising, subscription and publications sales, or exhibitor fees and meeting registrations need not be disclosed.
>
> At a minimum, organizations must disclose amounts received from corporations identified on Schedule B of their Form 990 (more than the greater of $5,000 or 2% of the total amount of contributions reported on line 1e of Part 1 of Form 990 (2007), line 1 h of Part VIII of Form 990 (2008)). The disclosure information should be posted on the organization's website in an easily accessible location within six months of the close of the organization's fiscal year. Disclosure should include the name of the corporation and the aggregate amount of support provided by that corporation. Such disclosure may be reported in ranges, e.g. $0 - $50,000; $50,001 - $100,000, etc. Disclosure should also include the total amount of all corporate support received from all corporations.

The complete NHC Standards of Excellence™ can be found at http://www.nationalhealthcouncil.org/pages/standards.php.

Corporate Relations Review Committee

All proposed AHA national and multi-affiliate corporate relationships are reviewed by a volunteer Corporate Relations Review Committee (CRRC) and senior staff External Relations Committee (ERC) to assess compliance with the Corporation Relations Policy and to assess the risks of the relationship versus benefits. The CRRC has seven volunteer members consisting of a chairperson appointed jointly by the Chairman of the Board and the President of AHA; two medical members; two lay members, one with development expertise; one member with nutrition expertise; and one member with communications and marketing expertise. Members serve two-year staggered terms, with service generally limited to two consecutive two-year terms.

The Conflict of Interest Policy is on every meeting agenda for the CRRC/ERC and other AHA committees, and is more fully discussed below.

Linking Policy

AHA's Linking Policy is at:
http://www.americanheart.org/presenter.jhtml?identifier=6894 and provides:

> Any link from the AHA/ASA Web site to an external Web site must abide by a two-click rule. This means that the first link goes to a "jump page" that explains the relationship between AHA/ASA and the other party. A link to the [sponsor's] external Web site can be placed on this jump page, however, it must land on a general homepage, not a page that includes information about specific products or services.

AHA's standard corporate sponsorship agreement requires that all corporate sponsors comply with this policy.

Non-endorsement Policy

AHA policy prohibits endorsement of a specific commercial product, process, service or enterprise. There are limited exceptions that can only be approved by the AHA Board of Directors, such as the food certification program. The policy is found at **Tab 2.**

Conflict of Interest Policy

AHA's Conflict of Interest Policy, a copy of which may be found at **Tab 3,** requires that AHA, its affiliates and components, and all officers, directors, delegates, council and committee members scrupulously avoid any conflict between their own respective personal, professional or business interests and the interests of AHA in any and all actions taken by them on behalf of AHA in their respective capacities. The policy further requires officers, directors, delegates, council or committee members to give notice of any conflict and abstain from discussing, voting or attempting to influence any AHA matter in which the individual has a personal financial, employment or business interest. This policy has been in place since June 1986.

Conflict of Interest Standards

The AHA Conflict of Interest Standards (**Tab 4**) acknowledge that volunteers have myriad relationships, interests, and memberships which enhance their expertise and provide value to AHA, and provide guidelines to volunteers to avoid situations that potentially may affect or compromise the integrity and independence of AHA's decision-making processes, confidence in AHA or AHA's reputation. The Standards set out expectations regarding behavior, disclosure and abstention. The Standards discuss the handling of gifts and honoraria, self-dealing transactions, and overlapping memberships. Additionally, the Standards set out specific criteria for AHA Officers, AHA Journal Editors, and AHA budget/audit committee members. The Standards establish a Conflict of Interest Review Committee that reviews incoming AHA Officers, Journal Editors, and the Chief Executive Officer for conflicts of interest. The Standards also stipulate that staff shall comply with the Conflict of Interest Policy and Standards.

Conflict of Interest Procedures

Annually the General Counsel & Corporate Secretary distributes to staff the Conflict of Interest Procedures memo (**Tab 5**). It provides guidance to those staff who are responsible for managing AHA boards, committees and other volunteer groups, and also provides the procedures for staff who are required to submit conflict of interest disclosures. Staff responsibilities for managing boards, committees and other volunteer groups generally include: 1) nominating volunteers and staff to serve on the committee, task force or writing group in conjunction with the chairperson of the volunteer group, which nominations are approved by the Officers; 2) reviewing committee member Disclosure Questionnaires; 3) working with the group's chairperson to resolve

any identified conflicts of interest, and forwarding conflicts that cannot be resolved to the General Counsel & Corporate Secretary and Conflict of Interest Review Committee (described below); 4) draft meeting agendas and exhibits for approval by the chairperson; and 5) prepare minutes detailing the discussion and decisions for approval by the chairperson.

Annually during their term of service, AHA officers, directors, committee, subcommittee, task force, working group, writing group and Council members, and Journal Editors are asked to review the AHA Conflict of Interest Policy & Record of Abstention Form and the AHA Conflict of Interest Standards. They are reminded of the Conflict of Interest Policy and requirement that during a meeting, if a direct or indirect conflict of interest arises, they must disclose the actual or potential conflict, and refrain from any discussion and voting on that matter. In that event, the volunteer is to note the actual or potential conflict of interest on the Record of Abstention form, sign it, and give it to the committee chairperson or staff. The Record of Abstention form will be filed with the minutes of the meeting to record the volunteer's disclosure and abstention.

Disclosure Questionnaire

Further, upon appointment to a committee or other group, the volunteer is asked to submit a Conflict of Interest Disclosure Questionnaire **(Tab 6)**. Volunteers are advised to report any material changes in their situation that occurs after completion of the Questionnaire by updating their Disclosure Questionnaire on file or submitting a new Disclosure Questionnaire. Subsequently, the volunteer is requested to review and update the Disclosure Questionnaire annually.

Volunteers are told that the Disclosure Questionnaire will be treated as confidential, and is intended solely for AHA's purposes to facilitate identification, disclosure and resolution of potential conflicts of interest. These Disclosures are treated as confidential to encourage full and frank disclosure of potential conflicts.

As part of the Disclosure Questionnaire, volunteers and specified staff must provide the following disclosures regarding other financial or business interests (other than employment):

1. List the names of any other financial or business relationship or interest including for-profit corporations, companies, business enterprises, partnerships or organizations; not-for-profit associations, organizations or institutions; and federal or state government agencies with which you or a member of your immediate family or household have a relationship and which: (1) do or propose to do business with AHA; (2) provide competing services, programs or publications similar to or competing with AHA; (3) engage in fund raising activities similar to AHA or compete for charitable funding; (4) engage in research funding or compete for scientific or research funding; (5) are involved with pharmaceutical, biomedical, or biomedical device companies; or (6) any entity in these categories provides funds to you or members of your

immediate family or household. The relationship could be as an officer, director, owner, partner, manager, member, volunteer, trustee, broker, editor, advisor, consultant, speakers' bureau, investment advisor, or grantee.

2. List any companies or organizations identified in sections I or II above in which you have a significant* direct or indirect financial interest through compensation, funding, stock ownership or options, bonds, promissory notes, patents or intellectual property ownership, trusts or other arrangements:

   *It is a "significant" interest if (a) you receive $10,000 or more annually or it represents 5% or more of your gross income for the previous year; or (b) you own 5% or more of the voting stock of the entity, or own $10,000 or more of the fair market value of the entity.

Specific Conflict of Interest Processes

AHA has additional specific conflict of interest processes in place to ensure the scientific integrity of its activities.

The Board of Directors has established the Science Advisory & Coordinating Committee (SACC) as the AHA's highest scientific body. Among other things, SACC approves the AHA position on appropriate scientific topics; monitors new developments in cardiovascular science to determine and adjust the AHA's scientific agenda appropriately; manages the process of commissioning, reviewing and approving appropriate medical and scientific statements and guidelines of importance to the AHA mission and science agenda; and oversees the Research Committee, Scientific Publishing Committee, and Scientific Sessions Program Committee. SACC and its subcommittees have developed rigorous procedures for handling conflict of interest issues, including:

- At **Tab 7**, AHA provides the conflict of interest processes for: 1) creation and processing of AHA Scientific Statements from appointment of the writing group up to and through the publishing process; and 2) the 11 peer reviewed journals that AHA publishes. Exhibits A through Exhibit C set out the AHA process for appointment of writing groups charged to develop AHA scientific statements and guidelines, including conflict of interest rules, and the process for reviewing conflicts at various steps during the course of the writing and publication of AHA scientific statements and guidelines. Exhibits E and F set out the AHA process for peer review of scientific manuscripts submitted for publication in AHA journals, including peer review and the disclosure of relationships with industry of the authors of the paper when the paper is published.

  Exhibit D at Tab 7 describes how AHA regularly discloses support by pharmaceutical, device and other companies in its news releases about a scientific study, statement or guidelines. News releases include the statement "Disclosures for individual authors are available on the manuscript" at the end of the release.

Regular journal news releases:

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.

AHA scientific statements/guidelines/position papers, etc. news releases:

The American Heart Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.

AHA Scientific Sessions and small meetings news releases:

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.

ASA International Stroke Conference news releases:

Statements and conclusions of study authors that are presented at American Heart Association/American Stroke Association

scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.

- At **Tab 8**, AHA provides the AHA process for complying with ACCME standards regarding industry sponsored professional education that, among other things, precludes the involvement of a corporate funder with the development of the curriculum.

- At **Tab 9**, AHA provides the AHA process for selection of speakers at AHA Scientific Sessions. Among other things, a speaker's relationships with industry are disclosed in the program or at the time of the presentation.

The Science Advisory & Coordinating Committee is comprised of the President who serves as chairperson, and President-elect who serves as vice chairperson. Other members include: Immediate Past President, chairpersons of the following: each Scientific Council, Council Operations Committee (COC), Scientific Sessions Program, Scientific Publishing, Research, ECC, and Professional Education Committees; four (4) AHA Scientific members who represent Affiliate interests as well as AHA science interests, (such members may already be serving on SACC; if not, an At-large member(s) shall be selected.); one Early Career Investigator; external liaisons from government agencies, as determined by the President; and At-large members as appropriate. The membership provides a breadth of scientific and medical expertise. SACC's science-based composition, size and the conflict of interest rules safeguard against inappropriate undue influence.

Conflict of Interest Review Committee

The Conflict of Interest Standards establish a Conflict of Interest Review Committee to advise the General Counsel & Corporate Secretary on conflict of interest matters, respond to questions, or make recommendations regarding conflict of interest issues and interpretations or amendments of the Conflict of Interest Policy and Standards.

Annually, the Conflict of Interest Review Committee reviews the Disclosure Questionnaires of incoming Officers, Journal Editors, and the Chief Executive Officer, and determines if any conflicts of interest exist that need to be resolved, which, for the Officer nominees and editor candidates, must be before election or appointment. For the medical Officers and Journal Editors, the outcome is that they resign or suspend their relationships with pharmaceutical or device

companies in the CVD and stroke fields, or fields related to their journal topic for the Editors, for the duration of their service as an Officer or Editor with an occasional exception for a strong justification.

The Committee is comprised of two past Chairmen of the Board and two past Presidents of AHA; the chairperson of the Scientific Publishing Committee; the General Counsel; and the Senior Internal Auditor. The former chairmen and presidents serve for staggered three-year terms.

b. Explain policies on disclosure of outside income by your top executives and board members.

Conflict of Interest Policy, Standards and Procedure

See above

Human Resources Policy

AHA's employment policies provide:

> A staff member will not engage in outside employment, self-employment or other activities, which would constitute a conflict of interest, reflect adversely on the AHA, or adversely affect the staff member's AHA performance. Staff members will not use AHA time or resources for non-AHA work or for any personal or private gain. A conflict of interest exists in such instances when a regular or temporary employee:
>
> a. Accepts full or part-time employment in, or retains as a customer or client when self-employed, any organization which does business with or for the AHA.
> b. Gives AHA business to a firm in which he or she has financial or personal interest.
> c. Advises or recommends AHA activities or programs from which they or their non-Association employer expect to gain financially.
> d. Accepts full or part-time employment with or becomes self-employed in an activity or enterprise that competes with the AHA or that provides similar products or services to those of the AHA.
> e. Runs for or holds an elected office.
>
> While on leave, a staff member is not permitted to engage in any outside employment or self-employment. Doing so is grounds for disciplinary action, up to and including termination of employment.

IRS Form 990

Current year available on AHA's web site at:
http://www.americanheart.org/presenter.jhtml?identifier=3044259

Prior years are available at **Tab 10**.

c. Provide the disclosures of outside income filed by top executives and board members.

The AHA Disclosure Questionnaire requests that volunteers disclose relationships in six defined categories and asks that those relationships with a value of $10,000 or more or 5% or more of gross income be identified. As discussed with your staff on January 25, 2010, AHA has a great deal of concern about disclosing personally identifiable financial information of individual Board members in response this request. AHA represents to volunteers that this information is confidential and used for AHA's purposes, and obtains and maintains this information in a confidential manner. AHA is deeply concerned that providing the disclosures of all Board members for the last five fiscal years will have the undesirable consequences of individuals disclosing less personal financial information to AHA in AHA's conflict of interest process and deciding not to be an AHA Board member to avoid being subject to such public disclosures. AHA's ability to effectively manage conflicts of interest rests on its strong policies and procedures, and also on the willingness of AHA volunteers to fully participate in the process and fully disclose relevant conflicts.

Nonetheless, to provide the Committee information relevant to their inquiry, AHA is providing aggregate information on the number and percentage of individual Board members who have disclosed relationships with a pharmaceutical, device, or insurance company, or a foundation related to those three industries as follows.

Board

The Board of Directors is the final authority on operations of the American Heart Association consistent with the Certificate of Incorporation and the Bylaws. To fulfill its responsibilities, the Board creates committees, councils and other groups, including the Science Advisory & Coordinating Committee (SACC), the AHA Research Committee, the Conflict of Interest Review Committee, and the Corporate Relations Review Committee that include Board members, other AHA volunteers and external members. The Board does not approve scientific statements or guidelines which, as discussed earlier, is a process overseen by SACC and which includes rigorous Conflict of Interest procedures in the appointment and the work of the writing group chairperson and members, which can be found at **Tab 7**.

AHA Bylaws set out the responsibilities, composition and terms of AHA's Board of Directors. The Board is comprised of 22 members, all of whom serve without compensation.

The Board of Directors is composed of the following: seven Officers who are the Chairman of the Board, Chairman-elect, Immediate Past Chairman, President, President-elect, Immediate Past President, and Secretary-Treasurer; one member from each of the eight AHA Affiliates; two Science members; the chairpersons of the AHA Research Committee and of the American Stroke Association Advisory Committee; and three external At-large members. The

Board of Directors is nominated and elected by the Nominating Committee in accordance with the Bylaws.

Other than the Officers who have one-year terms, other directors serve staggered two-year terms with eligibility to serve two consecutive full terms.

For the period 2005-2006 through 2009-2010, 53 individuals have served on AHA's Board of Directors. Pursuant to the Conflict of Interest Policy procedures, the disclosure questionnaires of those Board members were reviewed by the General Counsel & Corporate Secretary. In addition, the disclosure questionnaires of those Board members also serving on committees or task forces were reviewed by the staff responsible for managing those committees or task forces, as described earlier. Further, the Conflict of Interest Review Committee reviewed 16 of those 53 individuals since those members were incoming officers or journal editors.

- Forty of the 53 Board members (75.5% of total) did not report any relationships with pharmaceutical, device, or insurance companies or their foundations.
- Thirteen of the 53 Board members (24.5% of total) reported relationships with pharmaceutical, device, or insurance companies or their foundations.
    - Of these 13, three reported only one relationship, which was an employment relationship with a device or insurance company. One of those three was also reviewed by the Conflict of Interest Review Committee because he was an incoming Officer.
    - Of the remaining 10 that reported relationships, four members were reviewed by the Conflict of Interest Review Committee, since three were incoming Officers and one was an incoming Journal Editor following his service on the Board.
    - For the medical Officers and Journal Editors, as previously noted, the outcome of this review is that they resign or suspend their relationships with pharmaceutical or device companies in the CVD and stroke fields, or fields related to their journal topic for the Editors, for the duration of their service as an Officer or Editor with an occasional exception for a strong justification.

CRRC

Because the Corporate Relations Review Committee (CRRC) is responsible for approving corporate relationships, AHA is additionally providing information on the Conflict of Interest Disclosures for members of the CRRC as follows:

- Two of the 19 members (10.5%) who served from 2005-2006 through 2009-2010 reported relationships with the pharmaceutical or device industries.

- As noted, pursuant to the Conflict of Interest Policy procedures, the disclosure questionnaires of volunteers who serve on committees are reviewed by appropriate staff responsible for the committee. Members who have relationships with companies presenting proposals to CRRC are required to abstain from reviewing or voting on those proposals.

Senior Staff

During the time period of 2005-2006 through 2009-2010, no member of the Strategic Leadership Team (which currently includes the Chief Executive Officer, Chief Mission Officer, Chief Administrative Officer, Chief Operating Officer and the 8 National Center Executive Vice Presidents), reported relationships with pharmaceutical, device, or insurance companies or their foundations.

In summary, AHA is proud of our record of leadership and transparency in the disclosure of industry funding and implementation of strong corporate relations and conflict of interest policies and procedures to protect the integrity of AHA science. We share your concern for protecting the public interest while improving medical knowledge and care, and we are confident that this information will demonstrate to you our concern and commitment. If you have any further questions, please do not hesitate to contact me.

Since

David
Executive Vice President, Corporate Secretary
and General Counsel

DWL/lmd

Grand Total	108,866,840		
Name of Company	Amount of Funding	Year	Reason(s) that the funding was provided
Abbott	15,000	FY05-06	conference -Sessions 2005 LBCT CD-ROMs
Amgen	100,000	FY05-06	conference - Prevention VIII
Amgen	2,500	FY05-06	conference -BCVS 2006
Amylin	5,000	FY05-06	conference - Obesity 2006
AstraZeneca	800,000	FY05-06	sponsorship - Search Your Heart
AstraZeneca	150,000	FY05-06	unrestricted donation - Charitable Donation from Byron Nelson Classic
AstraZeneca	10,000	FY05-06	conference - HBPR 2005
AstraZeneca	62,000	FY05-06	International Stroke Conference - 2007
AstraZeneca	7,200	FY05-06	conference - Sessions 2005
AstraZeneca	50,000	FY05-06	Sessions 2005 AstraZeneca - Atacand Mini Shuttle Bus Pkg.
AstraZeneca	62,000	FY05-06	Stroke Conference 2006 - Communication Centers
AstraZeneca	895,000	FY05-06	Sessions 2006 - Expo-Card and Pre Reg Mailer, Final Program, Fun Run/walk, Pedometers, Shoulder Bags, & Shuttle Bus Pkg., Pens & Pads Inserts for Shoulder Bags; 7 banners
AstraZeneca	40,000	FY05-06	conference -State-of-the-Art Nursing Symposium
Bayer	25,000	FY05-06	conference - Sessions 2006
Bayer	25,000	FY05-06	conference - Sessions 2005 Ad Banner
Bayer	10,000	FY05-06	misc councils
BMS	50,000	FY05-06	conference - STEMI 2006
BMS	30,000	FY05-06	conference - High Risk Plaque
BMS	185,000	FY05-06	Stroke Conference 2006 - Ad Banners (3), Key Cards, Pre Reg Mailer, Posters on CD, and Prelim & Final Programs
BMS	500,000	FY05-06	conference - HIV Grant
BMS/Sanofi	20,000	FY05-06	conference - Prevention VIII
BMS/Sanofi	345,000	FY05-06	Sessions 2006 - Portable page markers and notes, final program book; 4 communications centers
BMS/Sanofi	285,000	FY05-06	Sessions 2005 - Comm Centers & Final Program Back Cover

Grand Total	108,866,840		
Name of Company	**Amount of Funding**	**Year**	**Reason(s) that the funding was provided**
BMS/Sanofi	285,000	FY05-06	Sessions 2005 - PDA Snap Guide, Page Markers & Notes, and 3 Ad Banners
BMS/Sanofi	35,000	FY05-06	Educational Grant - PAD -- ACC/AHA Materials for ACP Chapter Meetings
BMS/Sanofi	35,300	FY05-06	Educational Grant - PAD -- ACC/AHA Materials distributed with ACP Observer
BMS/Sanofi	275,000	FY05-06	Educational Grant
BMS/Sanofi	300,100	FY05-06	Educational Grant
BMS/Sanofi	2,500,000	FY05-06	Educational Grant
BMS/Sanofi	75,000	FY05-06	sponsor (no contract in Finance)
BMS/Sanofi	350,000	FY05-06	sponsorship - PAD -- CME/CE Certified Multimedia Educational Events
BMS/Sanofi	1,050,000	FY05-06	sponsorship - Power to End Stroke
Boehringer Ingelheim	125,000	FY05-06	Stroke Conference 2006 - Abstracts on CD, Lanyards, Shoulder Bags w/ P&P
Boehringer Ingelheim	30,000	FY05-06	Stroke Conference 2006 - Ad Banners
Boehringer Ingelheim	15,000	FY05-06	sponsorship of council award - William M. Feinberg Award for Excellence in Clinical Stroke
Boehringer Ingelheim	400,000	FY05-06	Educational Grant - GWTG-Stroke Program Getting Started -- CME accredited program
CV Therapeutics	82,000	FY05-06	conference - Diagnosis & Treatment of Women with Ischemic Heart Disease
CV Therapeutics	15,000	FY05-06	conference - QCOR 2006
CV Therapeutics	10,000	FY05-06	conference - STEMI 2006
CV Therapeutics	10,000	FY05-06	conference - 5th Hypertension Summer School
CV Therapeutics	500	FY05-06	sponsorship of council award - Early Clinical Practice Leadership Nursing Award
CV Therapeutics	10,000	FY05-06	sponsorship of council award - New Investigator Award for European Fellows

Grand Total	108,866,840		
Name of Company	**Amount of Funding**	**Year**	**Reason(s) that the funding was provided**
Cytokinetics	3,000	FY05-06	conference - BCVS 2006
Eli Lilly	50,000	FY05-06	conference - STEMI 2006
Genentech	100,000	FY05-06	Educational Grant - NIH Stroke Scale
Genentech	8,333	FY05-06	sponsorship - On-line NIH Storke Scale Program
Genentech	25,000	FY05-06	Stroke Conference 2006 - PDA Snap Guide & Beaming Station
Genentech	5,000	FY05-06	
Genzyme	5,000	FY05-06	conference -BCVS 2005
GlaxoSmithKline	1,625,000	FY05-06	sponsorship - GWTG Heart Failure
GSK	50,000	FY05-06	conference - High Risk Plaque
GSK	25,000	FY05-06	conference - Prevention VIII
GSK	20,000	FY05-06	conference - Sessions 2005 - Tab Divider
Guidant	10,000	FY05-06	conference
Kos	800,000	FY05-06	Sponsor/Advertising - Web-themed Communities
Kos	400,000	FY05-06	sponsorship - Cholesterol Heart Profilers
Laerdal	5,000	FY05-06	conference
Medtronic	20,000	FY05-06	conference
Merck	12,000	FY05-06	sponsorship of council award - Merck New Investigator Awards
Merck & Co.	39,000	FY05-06	conference - High Blood Pressure - 2006
Merck & Co.	10,000	FY05-06	conference - Clinical Mgmt. of Hypertension 2006
Merck & Co.	10,000	FY05-06	conference - Obesity 2006
Merck & Co.	5,000	FY05-06	conference - High Blood Pressure - 2006
Merck & Co.	25,000	FY05-06	conference - Sessions 2006 - 1 additional banners for Nancy Nolan
Merck & Co.	50,000	FY05-06	conference - Sessions 2006 - 2 additional banners for John Wasilewski
Merck & Co.	50,000	FY05-06	conference - Sessions 2006 - 2 banners (M&Co. John Wasiliewski)
Merck & Co.	50,000	FY05-06	conference - Sessions 2006 - 2 banners (M/SP Nancy Nolan)
Merck & Co.	50,000	FY05-06	conference - Sessions 2006 - Exhibit Hall Locator Maps

Grand Total	108,866,840		
Name of Company	Amount of Funding	Year	Reason(s) that the funding was provided
Merck & Co.	5,000	FY05-06	conference - Ten-Day 2006
Merck & Co.	170,000	FY05-06	conference -Sessions 2006 - Tuesday daily newspaper, PDA power-up, Posters-at-a-glance, Tab divider (Councils Acts/Sat. program)
Merck & Co.	45,000	FY05-06	conference - Prevention VIII
Merck & Co.	10,000	FY05-06	conference - High Risk Plaque
Merck & Co.	20,000	FY05-06	conference - Sessions 2005 - Council Tab Divider
Merck/Schering-Plough	900,000	FY05-06	Educational Grant - GWTG CAD
Merck/Schering-Plough	100,000	FY05-06	Educational Grant-CME -GWTG CAD
Merck/Schering-Plough	25,000	FY05-06	conference - ATVB - 2006
Merck/Schering-Plough	10,000	FY05-06	conference - QCOR 2006
Merck/Schering-Plough	1,050,000	FY05-06	sponsorship - cholesterol website
Millar Instruments	7,500	FY05-06	conference
Millennium	10,000	FY05-06	conference - Sessions 2005 Interventional Fellows and Cardiologists Symposium
Myogen	5,000	FY05-06	conference - BCVS 2006
NitroMed	265,000	FY05-06	commercial support for independent medical education - ACP Report on African Americans Living with Heart Failure
NitroMed	15,000	FY05-06	conference - BCVS 2005
NitroMed	22,000	FY05-06	conference - QI Summit Pre-Sessions Event - reception support
Novartis	175,000	FY05-06	conference - Sessions 2005 - DART Trans, Heart Failure 2005, and Ad Banners #2 & 13
Novartis	10,000	FY05-06	conference - BCVS 2006
Novartis	20,000	FY05-06	sponsorship of council award - Novartis Award for Hypertension Research
NovoNordisk	5,000	FY05-06	conference - Ten-Day 2006
Omron	10,000	FY05-06	conference
Otsuka	10,000	FY05-06	sponsorship of council award - Arteriosclerosis/Heart Failure Translational Research Prize

Grand Total	108,866,840		
Name of Company	Amount of Funding	Year	Reason(s) that the funding was provided
Pfizer	5,000	FY05-06	conference - 5th Hypertension Summer School
Pfizer	75,000	FY05-06	conference - Sessions 2005 - 3rd Laptop Lounge and 10,000 additional CD-Roms for Abstracts on CD-ROM
Pfizer	100,000	FY05-06	conference - Sessions 2006 - 4 banners (they had 5 last year)
Pfizer	1,180,000	FY05-06	conference - Sessions 2006 - Abstracts on CD-ROM, 2 Daily Nespapers, Comm Center (1), Key Cards, Laptop Lounge, Lanyards, Prelim Program, Sessions-at-a-Glance, Shuttle Bus Pkgs. (2), and Tab Dividers (2).
Pfizer	30,000	FY05-06	conference - Stroke Conference 2006 - Ad Banners
Pfizer	30,000	FY05-06	conference - International Stroke Conference - 2007 - Ad Banners
Pfizer	55,000	FY05-06	conference - QI Summit Pre-Sessions Event - educational program support
Pfizer	10,000	FY05-06	conference - Obesity 2006 - Global Pharma, Kanasas City, MO
Pfizer	373,026	FY05-06	conference - Satellite Broadcast Adolescent Hyperlipidemia
Pfizer	373,026	FY05-06	conference - Satellite Broadcast Post MI Patient
Pfizer	114,200	FY05-06	conference - Needs Assessment: Knowledge, Attitudes, and Practice Patterns of PCP in CVD Mgmt.
Pfizer	30,000	FY05-06	conference - High Risk Plaque
Pfizer	15,000	FY05-06	conference - BCVS 2006
Pfizer	5,000	FY05-06	conference - Ten-Day 2006
Pfizer	25,000	FY05-06	conference - Sessions 2005 - Inspra: Ad Banner #17
Pfizer	22,500	FY05-06	conference - International Stroke Conference - 2007 - Page Markers & Notes; 1 Tab Divider
Pfizer	17,500	FY05-06	conference - Stroke Conference 2006 - Page Markers and Notes
Pfizer	5,000	FY05-06	conference - Stroke Conference 2006 - Tab Divider (Posters)
Pfizer	10,000	FY05-06	sponsorship of council award - New Investigator Award for Japanese Fellows
Philips	15,000	FY05-06	conference

Grand Total	108,866,840		
Name of Company	**Amount of Funding**	**Year**	**Reason(s) that the funding was provided**
Reliant	265,000	FY05-06	Educational Grant - ACP/AHA Report on Triglyceride Management
Roche Diagnostics	75,000	FY05-06	conference - Sessions 2005 - SSOD Focus on HF
Sanofi-Aventis	50,000	FY05-06	conference -Obesity 2006
Schering-Plough	900,000	FY05-06	sponsorship - HBP website
Scios	2,500	FY05-06	conference - BCVS 2005
Siemens	9,999	FY05-06	conference
Takeda	10,000	FY05-06	conference - QCOR 2006
Takeda	360,000	FY05-06	conference - Sessions 2005 - Best of Sessions Satellite Broadcast & Webcourse
Takeda	20,000	FY05-06	conference - Sessions 2005 Promotional Postcard BOS
Takeda	75,000	FY05-06	conference - Sessions 2005 SSOD Focus on Diabetes and Heart Disease
Takeda	5,000	FY05-06	conference - ATVB - 2006
Takeda	250,000	FY05-06	Membership (PRT)
Wyeth	5,000	FY05-06	conference - Clinical Mgmt. of Hypertension 2006
Wyeth	500,000	FY05-06	Educational Grant - GWTG CAD Pursuit of Excellence workshops
Zoll Medical	15,000	FY05-06	conference
Acetlion Pharmaceuticals	4,071	FY06-07	conference - HBPR 2007
Amgen	10,000	FY06-07	conference - Outcomes 2007
AstraZeneca	(62,000)	FY06-07	conference - International Stroke Conference - 2007 - counted last year and then returned to AZ this year.
AstraZeneca	1,500	FY06-07	conference - Sessions 2006
AstraZeneca	5,000	FY06-07	conference - Outcomes 2007
AstraZeneca	6,000	FY06-07	conference - HBPR 2007 - EDU AstraZeneca - NIAs
AstraZeneca	10,000	FY06-07	conference - ATVB 2007
AstraZeneca	31,100	FY06-07	conference - EPI and Prevention
AstraZeneca	40,000	FY06-07	conference - State of the Art Stroke Nursing Symposium

Grand Total	108,866,840		
Name of Company	Amount of Funding	Year	Reason(s) that the funding was provided
AstraZeneca	44,057	FY06-07	conference - High Risk Plaque
AstraZeneca	50,000	FY06-07	conference - Scientific Sessions 2007 - ADV Ad Banners Loc #'s 49 & 77
AstraZeneca	65,000	FY06-07	conference - Scientific Sessions 2007 - SPO Fun Run/Walk
AstraZeneca	69,000	FY06-07	conference - Stroke Research Project
AstraZeneca	420,000	FY06-07	conference - Scientific Sessions 2007 - SPO Expo Card , Shoulder Bags, Pedometers
AstraZeneca	2,400,000	FY06-07	Membership (PRT)
AstraZeneca	100,000	FY06-07	sponsorship - Search Your Heart
AstraZeneca	6,000,000	FY06-07	sponsorship - Start!
AtCor Medical, Inc.	5,000	FY06-07	conference
Bayer	(25,000)	FY06-07	conference - Sessions 2006 - ADV counted last year and then refunded to Bayer this year.
Bayer Corporation	250,000	FY06-07	sponsorship - GRFW
Bayer Corporation	600,000	FY06-07	sponsorship - Start!
BMS/Sanofi	110,000	FY06-07	conference - Sessions 2006 - ADV Final Program Inside Front Cover + 3 Pages and (1) Ad Banner.
BMS/Sanofi	130,000	FY06-07	conference - International Stroke Conference - 2007 - Key cards @Hotel; Pre-Registration Mailer & Expo Cards; Preliminary Program & Final Program; E-Poster Theater
BMS/Sanofi	430,000	FY06-07	conference - Scientific Sessions 2007 -ADV/SPO Final Program Inside Front Cover + 3 pages, (ADV) Final Program Inside and Outside Cover (ADV) , Communication Centers - Portable Page Markers and Notes
Boehringer Ingelheim	400,000	FY06-07	CME grant - GWTG - Stroke
Boehringer Ingelheim	10,000	FY06-07	conference - Women in Cardiolgoy Luncheon - Women in Cardiology Networking Luncheon at AHA Scientific Sessions
Boehringer Ingelheim	15,000	FY06-07	conference - International Stroke Conference - 2007 - Women in Cardiology Networking Luncheon at AHA Scientific Sessions

Grand Total	108,866,840		
Name of Company	**Amount of Funding**	**Year**	**Reason(s) that the funding was provided**
Boehringer Ingelheim	125,000	FY06-07	conference - International Stroke Conference - 2007 - Abstracts on CD-ROM ; Lanyards ; Shoulder bags
Boehringer Ingelheim	150,000	FY06-07	conference - International Stroke Conference 2008 - SPO Abstracts on CD-Rom $60,000; Lanyards ; Shoulder Bag w/ Pads and Pens
Boehringer Ingelheim	165,000	FY06-07	conference - Scientific Sessions 2007 - SPO Shuttle Buses
Boehringer Ingelheim	373,286	FY06-07	conference - Secondary Stroke Satellite Broadcast
Boston Scientific	40,000	FY06-07	conference
Bristol-Myers Squibb Company	2,400,000	FY06-07	Membership (PRT)
Bristol-Myers Squibb/Sanofi-Aventis Partnership	350,000	FY06-07	sponsorship - Stroke Connection magazine
CV Therapeutics	7,200	FY06-07	conference - High Blood Pressure - 2006
CV Therapeutics	7,500	FY06-07	conference - HBPR 2007
CV Therapeutics	10,000	FY06-07	conference - Outcomes 2007
CV Therapeutics	300,000	FY06-07	conference - Angina Satellite Broadcast
CV Therapeutics	500	FY06-07	sponsorship of council award - Early Clinical Practice Leadership Nursing Award
CV Therapeutics	10,000	FY06-07	sponsorship of council award - New Investigator Award for European Fellows
Daiichi Sankyo-Lilly	25,000	FY06-07	conference - Outcomes 2007
Daiichi Sankyo-Lilly	25,000	FY06-07	conference - Scientific Sessions 2007 - ADV Ad Banner Loc #2 (ADV)
Daiichi Sankyo-Lilly	190,000	FY06-07	conference - Scientific Sessions 2007 - ADV/SPO Wed Daily Newspaper (ADV)& Plasma Screens
Data Sciences International	500	FY06-07	conference

Grand Total	108,866,840		
Name of Company	**Amount of Funding**	**Year**	**Reason(s) that the funding was provided**
Genentech	25,000	FY06-07	conference - International Stroke Conference - 2007 - Palm Pilot (PDA) Program
Genentech	71,000	FY06-07	conference - International Stroke Conference - 2007 - Stroke Science OnDemand
Gilead/Myogen	1,000	FY06-07	conference - BCVS 2007
GlaxoSmithKline	2,400,000	FY06-07	Membership (PRT)
GSK	5,500	FY06-07	conference - Flu Initiative
GSK	2,000	FY06-07	conference - Hypertension Summer School - 2007
Itamar Medical, Inc.	5,000	FY06-07	conference
King Pharmaceuticals	1,000,000	FY06-07	sponsorship - HBP Website
Laerdal	5,000	FY06-07	conference
Medtronic, Inc.	61,350	FY06-07	conference
Merck	12,000	FY06-07	sponsorship of council award - Merck New Investigator Awards
Merck & Co, Inc.	25,000	FY06-07	conference - ATVB 2007
Merck & Co, Inc.	40,000	FY06-07	conference - HBPR 2007 - SPO NIA and Dinner
Merck & Co, Inc.	50,000	FY06-07	conference - AHA Women in Cardiology Trainee Award
Merck & Co, Inc.	155,000	FY06-07	conference - Scientific Sessions 2007 - SPO Water Bottles
Merck & Co., Inc.	2,400,000	FY06-07	Membership (PRT)
Merck & Co., Inc.	6,000,000	FY06-07	sponsorship - GRFW
Merck Human Health	125,000	FY06-07	conference - Scientific Sessions 2007 - ADV Ad Banners Loc 3"s 80C, 62, 5, 6 & 7 (ADV)
Merck Research Institute	10,000	FY06-07	conference - International Stroke Conference - 2007
Merck Research Laboratories	3,000	FY06-07	conference - ATVB 2007
Merck/Schering-Plough	13,000	FY06-07	conference - High Risk Plaque
Merck/Schering-Plough	75,000	FY06-07	conference - Scientific Sessions 2007 - ADV Ad Banners Loc #'s 4, 45, 47 (ADV)
Merck/Schering-Plough	225,000	FY06-07	conference - Scientific Sessions 2007 - ADV/SPO Locator Maps (SPO), Monday Daily Newspaper (ADV), Pads & Pens (SPO)

Grand Total	108,866,840		
Name of Company	Amount of Funding	Year	Reason(s) that the funding was provided
Merck/Schering-Plough	800,000	FY06-07	Educational Grant - GWTG - CAD
Merck/Schering-Plough	200,000	FY06-07	Educational Grant-CME- GWTG - CAD
Merck/Schering-Plough	2,400,000	FY06-07	Membership (PRT)
Microlife	900,000	FY06-07	conference
Nikon Instruments/Mager Scientific, Inc.	500	FY06-07	conference
Novartis	75,000	FY06-07	conference - Scientific Sessions 2007 - ADV Preliminary Program (ADV)
Novartis	105,000	FY06-07	conference - Sessions 2006 (BU - WO 8177) ADV Wednesday Daily Newspaper and (2) Ad Banners - ADV
Novartis	345,000	FY06-07	conference - Sessions 2006 - SPO/ADV Shuttle Buses, Water Bottles and (1) Ad Banner - ADV
Novartis	2,400,000	FY06-07	Membership (PRT)
Novartis	890,000	FY06-07	sponsorship - Hypertension Primer
Novartis	20,000	FY06-07	sponsorship of council award - Novartis Award for Hypertension Research
Novo Nordisk	25,000	FY06-07	conference - Sessions 2006 - EDU Science OnDemand
Novo Nordisk	30,000	FY06-07	conference - International Stroke Conference - 2007 - Ad Banners 2 (ADV)
Otsuka	10,000	FY06-07	sponsorship of council award - Arteriosclerosis/Heart Failure Translational Research Prize
Pfizer	10,000	FY06-07	conference - HBPR 2007
Pfizer	15,000	FY06-07	conference - Sessions 2006 - SPO Hotel Elevator Television Monitors
Pfizer	20,000	FY06-07	conference - Hypertension Summer School - 2007
Pfizer	20,000	FY06-07	conference - Heart Failure in the Young (CVDY) 2007
Pfizer	20,000	FY06-07	conference - EPI and Prevention
Pfizer	23,339	FY06-07	conference - Outcomes 2007
Pfizer	24,160	FY06-07	conference - ATVB 2007

Grand Total	108,866,840		
Name of Company	Amount of Funding	Year	Reason(s) that the funding was provided
Pfizer	24,300	FY06-07	conference - BCVS 2007
Pfizer	24,500	FY06-07	conference - 10-Day 2007
Pfizer	50,000	FY06-07	conference - Scientific Sessions 2007 - ADV Ad Banners Loc #'s 13 & 59 (ADV)
Pfizer	62,000	FY06-07	conference - International Stroke Conference - 2007 - Communication Centers and Laptop Lounge
Pfizer	87,500	FY06-07	conference - International Stroke Conference 2008 - ADV/SPO Communication Centers Sponsorship, Laptop/Wi-Fi Lounge Sponsorship, Page Markers and Notes Sponsorship; Posters/Abstracts Tab Divider Advertising
Pfizer	374,000	FY06-07	conference - Ischemic Stroke Satellite Broadcast
Pfizer	995,000	FY06-07	conference - Scientific Sessions 2007 - ADV/SPO Abstracts on CD ROM Communication Center (1) Lanyards Laptop Lounges , Shuttle Bus Packages , Tab Divider in Final Program – General Information
Pfizer	1,784,075	FY06-07	conference - National Speaker Training Program
Pfizer - Japan	11,500	FY06-07	conference - High Blood Pressure - 2006
Pfizer Inc.	2,400,000	FY06-07	Membership (PRT)
Pfizer Inc.	25,000	FY06-07	sponsorship - PTES Luncheon
Pfizer- Japan	8,500	FY06-07	conference - BCVS 2006
Reliant Pharmaceuticals, Inc.	134,125	FY06-07	Educational Grant - Healthcare
Reliant Pharmaceuticals, Inc.	265,000	FY06-07	Underwriting LOA - Healthcare Brochures
Roche Diagnostics	700,000	FY06-07	Sponsor/Advertising - Web-Themed Communities
Sankyo	3,500	FY06-07	conference - 5th Hypertension Summer School
Sankyo Foundation of Life Science	8,729	FY06-07	conference - BCVS 2006
Sanofi-Aventis	400,000	FY06-07	sponsorship - CV ACP Brochure

Grand Total	108,866,840		
Name of Company	Amount of Funding	Year	Reason(s) that the funding was provided
Takeda	5,000	FY06-07	conference - Hypertension Summer School - 2007
Takeda	10,000	FY06-07	conference - Outcomes 2007
Takeda	10,000	FY06-07	conference - ATVB 2007
Takeda	75,000	FY06-07	conference - Sessions 2006 - SPO Plasma Screens
Takeda	387,000	FY06-07	conference - Scientific Sessions 2007 - EDU Best of Sessions 2007 Grant Approved
Takeda	387,000	FY06-07	conference - Sessions 2006 - EDU Grant Best of Sessions Satellite Broadcast, Webcourse, and Mailer
Takeda	2,150,000	FY06-07	Membership (PRT)
Takeda Pharmaceuticals North America	1,500,000	FY06-07	sponsorship - Heart of Diabetes
Takeda Pharmaceuticals North America	25,000	FY06-07	unrestricted donation
Wyeth	75,000	FY06-07	conference - Sessions 2006 - EDU Sessions Science OnDemand Focus on Cardio Metabolic Risk
Zoll Medical	10,000	FY06-07	conference
Abbott	117,941	FY07-08	special event sponsorship
Abbott	175,000.00	FY07-08	special event sponsorship
Aetna	375,000	FY07-08	special event sponsorship
Aetna	68,153	FY07-08	special event sponsorship
Aetna Foundation	200,000	FY07-08	special event sponsorship
Aetna Foundation	29,846	FY07-08	special event sponsorship
Aetna Inc.	442,500.00	FY07-08	special event sponsorship
AGA Medical	50,000.00	FY07-08	special event sponsorship
Applied Biosystems	10,000	FY07-08	conference
Astrazeneca	6,000	FY07-08	sponsorship of council award - New Investigator Award for European Fellows
AstraZeneca	509,000	FY07-08	conference
Bayer	115,000	FY07-08	special event sponsorship

Grand Total	108,866,840		
Name of Company	**Amount of Funding**	**Year**	**Reason(s) that the funding was provided**
Bayer	50,000.00	FY07-08	special event sponsorship
Biosite Inverness Medical	35,225	FY07-08	special event sponsorship
Blue Cross Blue Shield	155,000.00	FY07-08	special event sponsorship
Blue Shield of California	44,183	FY07-08	special event sponsorship
Blue Shield of California Foundation	51,462	FY07-08	special event sponsorship
Boehringer Ingelheim	800,000	FY07-08	conference
Boehringer Ingelheim	420,000	FY07-08	special event sponsorship
Boehringer Ingelheim Pharmaceuticals	400,000	FY07-08	sponsorship
Boston Scientific	558,800	FY07-08	special event sponsorship
Boston Scientific	108,814	FY07-08	special event sponsorship
Boston Scientific	217,500.00	FY07-08	special event sponsorship
Boston Scientific	25,000	FY07-08	conference
Bristol-Myers Squibb	1,219,871	FY07-08	conference
Cordis Corporation	20,000	FY07-08	special event sponsorship
Cordis Corporation	483,000	FY07-08	endowment
CV Therapeutics	500	FY07-08	sponsorship of council award - Early Clinical Practice Leadership Nursing Award
Daiichi Sankyo Lilly	933,353	FY07-08	conference
Edwards Lifesciences	30,714	FY07-08	special event sponsorship
Eli Lilly	1,800,000	FY07-08	Membership (PRT)
Ev3	125,000.00	FY07-08	special event sponsorship
Forest Laboratories	350,000	FY07-08	Sponsor/Advertising - Web-Themed Communities
Forest Laboratories	85,000	FY07-08	conference
Genentech	63,000	FY07-08	conference
GlaxoSmithKline	338,353	FY07-08	conference
Guidant	340,000	FY07-08	special event sponsorship

Grand Total	108,866,840		
Name of Company	**Amount of Funding**	**Year**	**Reason(s) that the funding was provided**
Guidant Foundation (Boston Scientific)	37,500.00	FY07-08	special event sponsorship
Hannaford Food and Drug	127,500	FY07-08	special event sponsorship
Harvard Pilgrim Healthcare	117,000	FY07-08	special event sponsorship
Health Net	413,755	FY07-08	special event sponsorship
Health Net Foundation	525,000.00	FY07-08	special event sponsorship
Japanese Companies	110,934	FY07-08	conference
Johnson & Johnson	125,000.00	FY07-08	special event sponsorship
King Pharmaceuticals	60,000	FY07-08	sponsorship - Local Event Activation
Labcorp of America	20,000	FY07-08	special event sponsorship
Laerdal	5,000	FY07-08	conference
Medtronic	138,045	FY07-08	special event sponsorship
Medtronic	350,000.00	FY07-08	special event sponsorship
Medtronic, Inc.	29,700	FY07-08	sponsorship
Medtronic/Physio-Control	50,000	FY07-08	conference
Merck	25,000	FY07-08	sponsorship of council award - Women in Cardiology Trainee Awards for Excellence
Merck	12,000	FY07-08	sponsorship of council award - Merck New Investigator Awards
Merck & Co.	141,000	FY07-08	special event sponsorship
Merck & Co., Inc.	203,000	FY07-08	conference
Merck & Co., Inc.	178,470	FY07-08	sponsorship
Merck / Schering Plough	250,000	FY07-08	special event sponsorship
Merck/Schering-Plough	185,000	FY07-08	conference
Merck/Schering-Plough	1,000,000	FY07-08	sponsorship
Northstar Neuroscience	29,700	FY07-08	sponsorship
Novartis	20,000	FY07-08	sponsorship of council award - Novartis Award for Hypertension Research
Novartis	65,000	FY07-08	conference

Grand Total	108,866,840		
Name of Company	**Amount of Funding**	**Year**	**Reason(s) that the funding was provided**
Novartis	104,000	FY07-08	special event sponsorship
Novo Nordisk	5,000	FY07-08	conference
Omron Healthcare, Inc.	1,125,000	FY07-08	sponsorship
Otsuka	10,000	FY07-08	sponsorship of council award - Arteriosclerosis/Heart Failure Translational Research Prize
Otsuka	425,000	FY07-08	conference
PDL Biopharma	75,985	FY07-08	conference
Pfizer	10,000	FY07-08	sponsorship of council award - New Investigator Award for Japanese Fellows
Pfizer	20,000	FY07-08	special event sponsorship
Pfizer	75,000.00	FY07-08	special event sponsorship
Pfizer Inc.	1,877,816	FY07-08	conference
Philips	25,000	FY07-08	Research Fellowship restricted donation
Philips	25,000	FY07-08	Research Fellowship restricted donation
Philips	20,000	FY07-08	conference
Philips	140,000	FY07-08	special event sponsorship
Roche Diagnostics	700,000	FY07-08	sponsorship
Solvay/Abbott	1,248,263	FY07-08	conference
St. Jude	37,500	FY07-08	conference
Takeda	225,800	FY07-08	conference
Takeda Pharmaceuticals	55,000.00	FY07-08	special event sponsorship
United Health Care	80,000.00	FY07-08	special event sponsorship
Zoll Medical	15,000	FY07-08	conference
Abbott	500,000	FY08-09	sponsorship - Patient Ed
Aetna	75,000	FY08-09	special event sponsorship
Allergan, Inc.	100,000	FY08-09	sponsorship - SC Magazine
Anthem BCBS of SC	67,500	FY08-09	special event sponsorship
Astellas	40,000	FY08-09	Educational Grant / CME
AstraZeneca	206,123	FY08-09	Educational Grant / CME

Grand Total	108,866,840		
Name of Company	Amount of Funding	Year	Reason(s) that the funding was provided
AstraZeneca	420,000	FY08-09	conference sponsorship/advertising
Bayer	75,000	FY08-09	special event sponsorship
Bayer Corporation	5,000	FY08-09	Educational Grant / CME
BCBS of SC	50,000	FY08-09	special event sponsorship
BCBS of TX	75,000	FY08-09	special event sponsorship
BG Medicine	150,000	FY08-09	special event sponsorship
Boehringer Ingelheim Pharmaceuticals	65,000	FY08-09	Educational Grant / CME
Boehringer Ingelheim Pharmaceuticals	255,000	FY08-09	conference sponsorship/advertising
Boston Scientific	15,000	FY08-09	Educational Grant / CME
Bristol-Myers Squibb Company	100,000	FY08-09	Educational Grant / CME
Bristol-Myers Squibb/Sanofi Partnership	1,613,497	FY08-09	sponsorship - PTES, SC Magazine, PAD Toolkits
Bristol-Myers Squibb/Sanofi Partnership	210,000	FY08-09	conference sponsorship/advertising
Cardinal Health	100,000	FY08-09	special event sponsorship
Codman & Shurtleff, Inc.	25,000	FY08-09	Educational Grant / CME
Codman & Shurtleff, Inc.	9,000	FY08-09	conference sponsorship/advertising
CV Therapeutics	50,000	FY08-09	conference sponsorship/advertising
Daiichi Sankyo Company	20,000	FY08-09	conference sponsorship/advertising
Daiichi Sankyo Lilly	35,000	FY08-09	Educational Grant / CME
Daiichi Sankyo Lilly	345,000	FY08-09	conference sponsorship/advertising
Ferrer Grupo	10,000	FY08-09	conference sponsorship/advertising
Forest Laboratories	81,250	FY08-09	sponsorship - Search Your Heart
Forest Laboratories	70,000	FY08-09	conference sponsorship/advertising
Genentech	100,000	FY08-09	Educational Grant / CME
Genentech	30,000	FY08-09	conference sponsorship/advertising

Grand Total	108,866,840		
Name of Company	**Amount of Funding**	**Year**	**Reason(s) that the funding was provided**
Gilead	5,000	FY08-09	Educational Grant / CME
Harvard Pilgrim Healthcare	220,000	FY08-09	special event sponsorship
Japanese Companies	126,376	FY08-09	Educational Grant / CME
Laerdal Medical	19,980	FY08-09	Educational Grant / CME
Medtronic Foundation	1,000,000	FY08-09	sponsorship - Youth Sudden Cardiac Arrest
Medtronic, Inc.	1,750,000	FY08-09	sponsorship - GWTG
Medtronic, Inc.	40,000	FY08-09	Educational Grant / CME
Merck & Company, Inc.	124,205	FY08-09	sponsorship - GRFW Cookbooks
Merck & Company, Inc.	96,000	FY08-09	Educational Grant / CME
Merck & Company, Inc.	205,000	FY08-09	conference sponsorship/advertising
Merck/Schering-Plough	600,000	FY08-09	sponsorship - GWTG
Merck/Schering-Plough	30,000	FY08-09	Educational Grant / CME
Merck/Schering-Plough	305,000	FY08-09	conference sponsorship/advertising
Novartis Pharmaceuticals	1,800,000	FY08-09	sponsorship - Hypertension Initiative
Novartis Pharmaceuticals	10,000	FY08-09	Educational Grant / CME
Novo Nordisk	85,000	FY08-09	conference sponsorship/advertising
OptumHealth	100,000	FY08-09	sponsorship - Start!
People's Health	75,000	FY08-09	special event sponsorship
Pfizer Inc.	500,000	FY08-09	sponsorship - GWTG
Pfizer Inc.	770,000	FY08-09	Educational Grant / CME
Pfizer Inc.	990,000	FY08-09	conference sponsorship/advertising
Philips	25,000	FY08-09	Research Fellowship restricted donation
Philips	25,000	FY08-09	Research Fellowship restricted donation
Philips	25,000	FY08-09	Research Fellowship restricted donation
Philips	25,000	FY08-09	Research Fellowship restricted donation
Philips	875,000	FY08-09	sponsorship - Start!
Philips	10,000	FY08-09	Educational Grant / CME
Phillips	155,000	FY08-09	special event sponsorship

Grand Total	108,866,840		
Name of Company	**Amount of Funding**	**Year**	**Reason(s) that the funding was provided**
Sanofi-aventis	150,000	FY08-09	special event sponsorship
Sanofi-Aventis	1,450,000	FY08-09	Membership (PRT)
Sanofi-Aventis	10,000	FY08-09	Educational Grant / CME
Sanofi-Aventis	120,000	FY08-09	conference sponsorship/advertising
Schering Corporation	663,000	FY08-09	sponsorship - GWTG
Schering-Plough	1,065,000	FY08-09	sponsorship - Hypertension website
Solvay/Abbott	(107,500)	FY08-09	Educational Grant / CME
St. Jude	25,000	FY08-09	Educational Grant / CME
St. Jude	42,500	FY08-09	conference sponsorship/advertising
Takeda Pharmaceuticals North America	43,500	FY08-09	Educational Grant / CME
Takeda Pharmaceuticals North America	70,000	FY08-09	conference sponsorship/advertising
United Healthcare	150,000	FY08-09	special event sponsorship
United Healthcare	42,750	FY08-09	sponsorship - PTES

A	B	C	D	E	F
	Total AHA Revenue per Audited Financial Statements	Total Pharma/Device/Insurance/ Related Foundation Revenue	Total Pharma/ Device/Insurance/ Related Foundation Revenue as a % or Total AHA Revenue	Actual National Center Pharma/Device Contributions posted on AHA web site	Comments
FY05-06	697,244,815	20,651,184	3.0%	19,663,684	Column C does not include Affiliate Revenue; difference between Column C and E is: 1) a $900K sponsorship that was erroneously not reported on web site; and 2) insurance revenue, which AHA does not report on its web site; in this fiscal year Column E reflects revenue booked and committed for single and multi-year relationships, not cash received as posted in subsequent fiscal years
FY06-07	799,369,613	48,331,292	6.0%	30,158,173	Column C does not include Affiliate Revenue; difference between Column C and E is: 1) insurance revenue, which AHA does not report on its web site; and 2) the difference between revenue that is booked and committed for multi-year relationships (Column C) and the cash actually received and available for use in AHA programs (Column E), which better reflects the level of support available for AHA programs
FY07-08	641,646,000	21,271,183	3.3%	22,018,695	Column C includes revenue from largest Affiliate Sponsorships; difference between Column C and E is: 1) inclusion of largest Affiliate sponsorships and insurance revenue, which AHA does not report on its web site; and 2) the difference between revenue that is booked and committed for multi-year relationships (Column C) and the cash actually received and available for use in AHA programs (Column E), which better reflects the level of support available for AHA programs
FY08-09	469,375,000	18,613,181	4.0%	21,516,691	Column C includes revenue from largest Affiliate Sponsorships; difference between Column C and E is: 1) inclusion of largest Affiliate sponsorships and insurance revenue, which AHA does not report on its web site; and 2) the difference between revenue that is booked and committed for multi-year relationships (Column C) and the cash actually received and available for use in AHA programs (Column E), which better reflects the level of support available for AHA programs
Grand Total	2,607,625,428	108,866,840	4.2%	93,357,243	